New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists

Annals of the Rheumatic Diseases

Volumn 65, Issue 3, 2006, Pages 405-407

  Kary, S ^a   Worm, M ^a   Audring, H ^a   Huscher, D ^b   Renelt, M ^c   Sorensen H ^d   Stander E ^e   Maass U ^a   Lee, H ^a   Sterry, W ^a   Burmester, G R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Rheumatology Research Center   (Germany)

^c Rheumatology Clinic   (Germany)

^d Hospital Schwerin ^*

^e Klinikum Suedstadt Rostock   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SKIN DEFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33144469041     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.037424     Document Type: Article

References (12)

1. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000;42:829-30.
2. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
3. Mease P. Psoriasis arthritis. TNFα therapy in psoriatic arthritis and psoriasis. How and why does it work? Ann Rheum Dis 2004;63:755-8.
4. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2001;144:118-21.
5. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587-9.
6. Schoen, MP, Boehncke WH. Medical progress. Psoriasis. N Engl J Med 2005;352:1899-912.
7. Kary S, Worm M, Fritz J, Audring H, Scherer HU, Lee H, et al. New onset or aggravation of psoriatic skin lesions in patients with definite rheumatoid arthritis under treatment with TNF-alpha-antagonists - report of 8 cases [abstract]. Ann Rheum Dis 2004;63(suppl.1):277.
8. Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. Psoriatic lesions induced by antitumour necrosis factor-α treatment: two cases. Br J Dermatol 2004;150:506-7.
9. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004;3:439-40.
10. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004;38:54-7.
11. Flendrie M, Vissers W, Creemers M, de Jong E, van de Kerkhof P, van Riel P. Dermatological conditions during TNF-alpha blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76.
12. Haibel H, Spiller I, Strasser C, Rudwaleit M, Dörner T, Sieper J. Unexpected new onset or exacerbation of psoriasis in treatment of active ankylosing spondylitis with TNF-alpha blocking agents: four case reports [abstract]. Ann Rheum Dis 2004;63(suppl.1):405.